Driven by our purpose, we are one of Australia’s leading sites for rapid study startup
We understand that delays in clinical trial startup can cost valuable time and resources. At Linear, we have a proven track record helping biotech and pharmaceutical companies accelerate their study activation. You too can utilise our experience and insight to leverage Australia’s streamlined regulatory environment, where no IND is required to commence your first-in-human trial, and ethics approvals can be achieved in as little as 4 weeks.
Our expert clinical operation teams are dedicated to reducing your clinical trial startup timeline by up to 6 months compared to trial undertaken in the US, helping you reach critical milestones faster, to improve return on your investment, and enable progression to stage II and III testing.
Why choosing Linear for fast clinical trial startup is proving effective
ICH-GCP compliance and
FDA standard infrastructure
We understand urgency
Whether you’re a global biotech launching a first-in-human study or expanding your pipeline into Asia-Pacific clinical trial sites, Linear offers speed, reliability, and scientific excellence.
Talk to us today and fast-track your clinical trial startup.
